<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630017</url>
  </required_header>
  <id_info>
    <org_study_id>207259</org_study_id>
    <secondary_id>Pro00068353</secondary_id>
    <nct_id>NCT02630017</nct_id>
  </id_info>
  <brief_title>Motivated Behavior in Adults With and Without ADHD</brief_title>
  <acronym>MOBE</acronym>
  <official_title>Motivated Behavior in Adults With and Without ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of methylphenidate on motivated behavior in adults with and&#xD;
      without ADHD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has a mixed between- and within-subject design. Participants are young adults&#xD;
      (aged 18-45) with ADHD and non-ADHD matched controls. They will be recruited from locations&#xD;
      around the community, consented, screened for eligibility, then scheduled for 2 study days.&#xD;
      Study days will be at least 48 hours apart. Thus, there will be a total of 3 lab visits&#xD;
      across a 3 week period. Participants will be administered study drug on one study day and&#xD;
      placebo on the other study day. They will complete a battery of cognitive/behavioral tasks&#xD;
      and answer questionnaires on both study days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2016</start_date>
  <completion_date type="Actual">September 21, 2018</completion_date>
  <primary_completion_date type="Actual">September 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>There are two parallel arms of this study (ADHD or non-ADHD subjects).&#xD;
Within each arm, each subject will be exposed to placebo and a drug (each at a different timepoint in the study). Although all subjects will receive both placebo and the drug, the order of presentation of the placebo and drug is counterbalanced across subjects (i.e., approximately half will receive the drug first and approximately half will receive the placebo first).&#xD;
For both study arms, regardless of whether the placebo is received first or second, the outcome measure will be calculated as the number of high effort selections.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of High-effort Selections in the Effort-based Decision Making Task</measure>
    <time_frame>1 hour post drug (or placebo) administration for each study session</time_frame>
    <description>Number of high-effort selections in the effort-based decision making task from the placebo to the methylphenidate condition. This is a decision-making task where participants make high- or low-effort choices to earn a small financial reward. High-effort selections require 100 button presses with non-dominant hand pinky finger and low-effort selections require 30 button presses with dominant hand index finger (within 15 seconds). The number of high effort selections are summed across 50 trials of the task. This task measures the willingness to perform effort in relation to changing reward magnitude and probability. This is a basic science experiment, the clinical and/or physiological relevance of these results are not established.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>ADHD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with ADHD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-ADHD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults without ADHD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADHD methylphenidate first, placebo second</intervention_name>
    <description>double-blind, counter-balanced administration</description>
    <arm_group_label>ADHD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADHD placebo first, methylphenidate second</intervention_name>
    <description>double-blind, counter-balanced administration</description>
    <arm_group_label>ADHD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-ADHD methylphenidate first, placebo second</intervention_name>
    <description>double-blind, counter-balanced administration</description>
    <arm_group_label>non-ADHD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-ADHD placebo first, methylphenidate second</intervention_name>
    <arm_group_label>non-ADHD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. generally healthy&#xD;
&#xD;
          2. between the ages of 18-45&#xD;
&#xD;
          3. non-ADHD subjects do not meet criteria for ADHD diagnosis or any subtype as determined&#xD;
             by the Conners Diagnostic Interview or any T-Score &gt; 55 on Inattentive Symptoms,&#xD;
             Hyperactive-Impulsive Symptoms, Total Symptoms or ADHD Index subscales of the CAARS.&#xD;
&#xD;
          4. ADHD subjects meet criteria for a primary diagnosis of ADHD, any subtype, based on&#xD;
             DSM-5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. inability to attend all required experimental sessions&#xD;
&#xD;
          2. significant health problems (e.g., current and uncontrolled liver, lung, or heart&#xD;
             problems, current or past seizure disorder, serious head trauma)&#xD;
&#xD;
          3. primary diagnosis of Axis I psychiatric disorders other than ADHD (e.g., depression,&#xD;
             anxiety disorder, schizophrenia)&#xD;
&#xD;
          4. meet DSM-5 criteria for substance use disorder other than nicotine in the past 12&#xD;
             months&#xD;
&#xD;
          5. use of psychoactive medications in the past 6 months as indicated by self-report&#xD;
&#xD;
          6. positive urine drug screen for drugs or positive breath alcohol concentration&#xD;
&#xD;
          7. contraindications for MPH&#xD;
&#xD;
          8. among women, nursing or a positive pregnancy test&#xD;
&#xD;
          9. IQ &lt; 80 on Kaufman Brief Intelligence Test, 2nd edition&#xD;
&#xD;
         10. allergy to lactose&#xD;
&#xD;
         11. hypertension (If subject is â‰¤ 40 years of age and has blood pressure over 135/85 or&#xD;
             heart rate over 90 beats per minute. If subject is &gt; 40 years of age and has blood&#xD;
             pressure over 130/80 or heart rate over 88 beats per minute)&#xD;
&#xD;
         12. body mass ratio &gt; 30&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merideth A Addicott, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>August 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2021</results_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02630017/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02630017/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Within each study arm (ADHD or non-ADHD subjects), subjects were exposed to placebo and drug (each at a different timepoint in the study). Approximately half of the subjects within each arm received drug first and half received placebo first (i.e., order was counterbalanced).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ADHD Methylphenidate First, Placebo Second</title>
          <description>Adults with ADHD who received drug (methylphenidate) first, followed by placebo</description>
        </group>
        <group group_id="P2">
          <title>ADHD Placebo First, Methylphenidate Second</title>
          <description>Adults with ADHD who received placebo first, followed by drug (methylphenidate)</description>
        </group>
        <group group_id="P3">
          <title>Non-ADHD Methylphenidate First, Placebo Second</title>
          <description>Adults without ADHD who received drug (methylphenidate) first, followed by placebo</description>
        </group>
        <group group_id="P4">
          <title>Non-ADHD Placebo First, Methylphenidate Second</title>
          <description>Adults without ADHD who received placebo first, followed by drug (methylphenidate)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ADHD</title>
          <description>Adults with ADHD</description>
        </group>
        <group group_id="B2">
          <title>Non-ADHD</title>
          <description>Adults without ADHD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="8"/>
                    <measurement group_id="B2" value="28" spread="7"/>
                    <measurement group_id="B3" value="31" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of High-effort Selections in the Effort-based Decision Making Task</title>
        <description>Number of high-effort selections in the effort-based decision making task from the placebo to the methylphenidate condition. This is a decision-making task where participants make high- or low-effort choices to earn a small financial reward. High-effort selections require 100 button presses with non-dominant hand pinky finger and low-effort selections require 30 button presses with dominant hand index finger (within 15 seconds). The number of high effort selections are summed across 50 trials of the task. This task measures the willingness to perform effort in relation to changing reward magnitude and probability. This is a basic science experiment, the clinical and/or physiological relevance of these results are not established.</description>
        <time_frame>1 hour post drug (or placebo) administration for each study session</time_frame>
        <population>Approximately half of the subjects within each arm (ADHD or non-ADHD) received drug first and half received placebo first (i.e., order was counterbalanced). The study was powered to compare two groups (ADHD vs non-ADHD). Since order of drug was counterbalanced, this means all ADHD subjects were evaluated under both placebo and drug conditions, and this is also true for the non-ADHD subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>ADHD Subjects, Placebo Condition</title>
            <description>Adults with ADHD, under the placebo condition</description>
          </group>
          <group group_id="O2">
            <title>ADHD Subjects, Methylphenidate Condition</title>
            <description>Adults with ADHD, under the methylphenidate (drug) condition</description>
          </group>
          <group group_id="O3">
            <title>Non-ADHD Subjects, Placebo Condition</title>
            <description>Adults without ADHD, under the placebo condition</description>
          </group>
          <group group_id="O4">
            <title>Non-ADHD Subjects, Methylphenidate Condition</title>
            <description>Adults without ADHD, under the methylphenidate (drug) condition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of High-effort Selections in the Effort-based Decision Making Task</title>
          <description>Number of high-effort selections in the effort-based decision making task from the placebo to the methylphenidate condition. This is a decision-making task where participants make high- or low-effort choices to earn a small financial reward. High-effort selections require 100 button presses with non-dominant hand pinky finger and low-effort selections require 30 button presses with dominant hand index finger (within 15 seconds). The number of high effort selections are summed across 50 trials of the task. This task measures the willingness to perform effort in relation to changing reward magnitude and probability. This is a basic science experiment, the clinical and/or physiological relevance of these results are not established.</description>
          <population>Approximately half of the subjects within each arm (ADHD or non-ADHD) received drug first and half received placebo first (i.e., order was counterbalanced). The study was powered to compare two groups (ADHD vs non-ADHD). Since order of drug was counterbalanced, this means all ADHD subjects were evaluated under both placebo and drug conditions, and this is also true for the non-ADHD subjects.</population>
          <units>Number of high-effort selections</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="2.2"/>
                    <measurement group_id="O2" value="21.35" spread="1.9"/>
                    <measurement group_id="O3" value="20.45" spread="2.2"/>
                    <measurement group_id="O4" value="19.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For each individual participant, 3 weeks (up to 60 days maximum)</time_frame>
      <desc>Data are being reporting according to the participant flow for the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>ADHD Methylphenidate First, Placebo Second</title>
          <description>Adults with ADHD who received drug (methylphenidate) first, followed by placebo</description>
        </group>
        <group group_id="E2">
          <title>ADHD Placebo First, Methylphenidate Second</title>
          <description>Adults with ADHD who received placebo first, followed by drug (methylphenidate)</description>
        </group>
        <group group_id="E3">
          <title>Non-ADHD Methylphenidate First, Placebo Second</title>
          <description>Adults without ADHD who received drug (methylphenidate) first, followed by placebo</description>
        </group>
        <group group_id="E4">
          <title>Non-ADHD Placebo First, Methylphenidate Second</title>
          <description>Adults without ADHD who received placebo first, followed by drug (methylphenidate)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merideth Addicott</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-526-8436</phone>
      <email>maddicott@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

